Seattle Genetics Wins Expanded Label for Lymphoma Drug

FDA expanded the label of Seattle Genetics’ Adcetris (brentuximab vedotin), approving its use in treating primary cutaneous anaplastic large-cell lymphoma and CD30-expressing mycosis fungoides, a common form of the disease.

The agency approved the expanded indication for the cancer drug a month before its Dec. 16 action date.

Adcetris was previously approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The approval derived from positive data from a Phase III trial as well as two Phase II trials.